Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibitors vs Calcineurin Inhibitors for ASS-ILD
NCT07406932Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- May 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Randomised, open-label trial in antisynthetase syndrome (ASSD) and interstitial lung disease (ILD) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: 12-month survival rate. Started May 2026; status: recruiting.
02
Conditions
antisynthetase syndrome (ASSD)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07406932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406932.